SEREAL||GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib Read more about SEREAL||GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib
Strategies to optimise the management of EGFR TKI-related side effects Read more about Strategies to optimise the management of EGFR TKI-related side effects
GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases Read more about GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
GIOTRIF vs gefitinib 1st line treatment EGFRm NSCLC Read more about GIOTRIF vs gefitinib 1st line treatment EGFRm NSCLC
GIOTRIF® provides ≥3 years long-term response even with dose modification Read more about GIOTRIF® provides ≥3 years long-term response even with dose modification
GIOTRIF® maintains efficacy despite dose modification Read more about GIOTRIF® maintains efficacy despite dose modification
